pharmaphorum October 31, 2025
Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the first approved therapy for rare inflammatory disease secondary hemophagocytic lymphohistiocytosis (sHLH).
The $183 million Series C is earmarked for Electra’s phase 2/3 trial of anti-SIRP-antibody ELA026 in sHLH, a hyperinflammatory disease that is triggered by another illness, such as an infection, autoimmune disease, or cancer, with sepsis-like symptoms that can be life-threatening.
The pivotal study is enrolling patients at research sites across the US and Europe and recently started dosing, said Electra in a statement. ELA026 has fast-track and breakthrough status from the FDA as well as a PRiME designation from the EMA for sHLH, based on phase 1b...
Today's Sponsors
Today's Sponsor